LianBio Company Description

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries.

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn’s disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy.

The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LianBio

Country	Cayman Islands
Founded	2019
Industry	Biotechnology
Sector	Healthcare
Employees	163
CEO	Adam Stone

Contact Details

Address: 103 Carnegie Center Drive Princeton, 08540 United States
Phone	609 486 2308
Website	lianbio.com

Stock Details

Ticker Symbol	LIANY
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US53000N1081
SIC Code	2836

Key Executives

Name	Position
Adam Leo Stone	Interim Chief Executive Officer and Director
Konstantin Poukalov	Founder and Executive Chairman
Ehong Gu	Interim Chief Financial Officer, Vice President and Head of Global Finance
Ji Chen	Senior Vice President and General Counsel
Brianne Jahn	Chief Business Officer
Levvy Lv D. Eng	Senior Vice President and Global Head of Development